Tri Locum Partners LP Abb Vie Inc. Transaction History

Tri Locum Partners LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $3.2 Million - $3.6 Million	23,246 Added 16.08%	167,807 $26 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $19.3 Million - $22.4 Million	144,561 New	144,561 $21.5 Million
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $7.12 Million - $8.2 Million	49,213 New	49,213 $7.84 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $23.7 Million - $29.5 Million	-179,950 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $19.3 Million - $24.5 Million	179,950 New	179,950 $24.4 Million
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $19.8 Million - $21.8 Million	-193,223 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $15.6 Million - $21 Million	193,223 New	193,223 $20.7 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

Stay updated on Tri Locum Partners LP with notifications on news.